SAN FRANCISCO — A $400 million pharmaceutical brawl lands in the First District Court of Appeal this month with the chance to make new law on lost profits, punitive damages and tortious interference in the context of a corporate acquisition.
Asahi Kasei Pharma Corp. of Japan scored the nine-figure win in 2011 when its lawyers at Morgan, Lewis & Bockius persuaded a jury that Actelion Ltd. acquired an Asahi business partner in order to shut down its development of Asahi’s potentially life-saving drug, fasudil.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
